Entry Date:
May 3, 2004

Trout Research Group: Molecular Engineering Laboratory

Principal Investigator Bernhardt Trout


The Molecular Engineering Laboratory at MIT, led by Prof. Bernhardt L. Trout, develops and applies sophisticated computational, theoretical, and experimental methods in order to probe complex chemical systems on the molecular level and engineer them for high value chemical applications with maximum specificity. Applications are currently in the fields of continuous pharmaceutical manufacturing, stabilization and formulation of biopharmaceuticals, and nucleation and crystallization. In parallel, we develop new computational methods which are generally applicable for the engineering of complex chemical systems.

Research areas:

(*) Continuous Pharmaceutical Manufacturing: Currently, pharmaceutical products are manufactured primarily using batch processes, as has been the industry standard from the beginning.  There is, however, tremendous potential to transform the entire industry by producing these products via continuous manufacturing. Moving to continuous has the potential for huge increases in efficiency, flexibility, and quality. As part of the Novartis-MIT Center for Continuous Manufacturing, a major effort in the Trout Group, together with the Hatton Group, focuses on the development of new technologies to effect continuous pharmaceutical manufacturing.  These include continuous crystallization processes together with a variety of novel separations and final finishing processes that have the potential to transform pharmaceutical manufacturing.

(*) Stabilization and Formulation of Biopharmaceuticals: Biopharmaceutical, including antibodies constitute the most rapidly growing class of human therapeutics for the treatment of numerous indications, including cancer, chronic inflammatory diseases and infectious diseases.  One of the major problems encountered in biopharmaceutical therapies is the inherent instability of biopharmaceuticals to degradation processes, such as aggregation, oxidation, hydrolysis, and deamidation.  The group has a major effort in developing a mechanistic and quantitative understanding of these processes, leading to new approaches to stabilizing biopharmaceuticals. Part of the work involves developing a mechanistic understanding how therapeutic antibodies aggregate during long-term storage.  We employ molecular simulation tools in collaboration with experimental techniques to elucidate aggregation mechanisms and determine molecular engineering strategies for antibody stabilization.

(*) Nucleation and Crystallization of Pharmaceuticals and Clathrate-Hydrates: Solution crystallization is a commonly used technique in the pharmaceutical industry to separate and purify API’s (Active Pharmaceutical Ingredients).  Understanding of crystallization together with nucleation is primarily based on heuristics and rough macroscopic models.  We aim to better control these processes via the development of molecular-based understanding.  Such understanding has the potential to make rational the solvent selection process and design of crystallization processes and therein streamline pharmaceutical development.

(*) Molecular Computational Methods for Reactive Processes in Complex Systems: The Molecular Engineering Laboratory at MIT was founded to develop cutting edge molecular computational methods and apply these methods to address important industrial problems.  Thus, a major aspect of the work in the Trout Group involves new molecular computational approaches based on statistical mechanics and quantum mechanics.  We are pursuing a number of new approaches to find reaction coordinates in complex systems.